Evidence From Humans
 
Print this page
Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.[see comment]
Xie, D., Shu, X. O., Deng, Z., Wen, W. Q., Creek, K. E., Dai, Q., Gao, Y. T., Jin, F., Zheng, W. Journal of the National Cancer Institute. 2000. 92:5, 412-7.
Topic area
Body size - Genetic variability
Study design
Population based case-control study
Study Participants
Menopausal Status
The menopausal status of women included in this study is listed here.
Pre menopausal
Post meopausal
Participant selection: Inclusion and exclusion criteria
Criteria used to select participants in the study.
Participants of the Shanghai Breast Cancer Study. Rapid case ascertainment system with population-based Shanghai Tumor Registry, pathologist confirmed diagnosis. Controls were selected by Shanghai Resident Registry and frequency matched by age in 5-year intervals.
Exposures investigated
BMI, Her2 allele frequencies, used PCR-RFLP
How exposure was measured
Biological Questionnaire, in-person
Ethnic groups with separate analysis
If this study provided a separate analysis by ethnic or racial group, the groups are listed here.
No
Confounders considered
Other breast cancer risk factors, such as family history, age at first birth, and hormone replacement therapy use, that were taken into account in the study.
Adequately controlled
Genetic characterization included
If the study analyzed relationships between environmental factors and inherited genetic variations, this field will be marked “Yes.” “No”, if not.
Yes
Description of major analysis
Logistic regression analysis of Her2 genotype and breast cancer, including effect modification by BMI
Strength of associations reported
Women with Val allele had an elevated risk of breast cancer, adjust OR=1.4 (CI: 1.0-2.0) with significant trend for increasing number of Val alleles
Stratification by BMI showed no effect modification
Privacy notice   |   Copyright statement